|
May 7
|
Compared to Estimates, Adaptive Biotechnologies (ADPT) Q1 Earnings: A Look at Key Metrics
|
|
May 7
|
Adaptive Biotechnologies Q1 2024 Earnings: Revenue Beats Estimates Amidst Challenges
|
|
May 7
|
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Misses Revenue Estimates
|
|
May 7
|
Adaptive Biotechnologies Reports First Quarter 2024 Financial Results
|
|
Apr 26
|
PhaseV and Quanticate partner to help sponsors run more adaptive trials
|
|
Apr 17
|
Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024
|
|
Apr 2
|
Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue
|
|
Mar 27
|
The 7 Best Penny Stocks to Buy in Q2 2024
|
|
Mar 27
|
Adaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024
|
|
Mar 11
|
Team behind popular Falcon AI models unveils new startup with $20 million in funding aimed at helping companies tailor LLMs for business
|
|
Dec 27
|
Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 9
|
Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting
|
|
Dec 5
|
Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting
|
|
Nov 7
|
Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ® Assay Across BeiGene’s Lymphoid Malignancy Pipeline
|
|
Nov 2
|
Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023
|
|
Oct 26
|
Adaptive Biotechnologies (ADPT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
|
|
Sep 13
|
Adaptive Announces Launch of Epic Integration for clonoSEQ®
|
|
Jul 19
|
Viking Global’s Performance, AUM, and Long-Term Stock Picks
|